AIM
LFCR icon

Acrospire Investment Management’s Lifecore Biomedical LFCR Stock Holding History

Acrospire Investment Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,722
Closed -$159K – 787
2017
Q2 		$159K Buy
10,722
+6,971
+186% +$97K 0.15% 53
2017
Q1 		$45K Sell
3,751
-82
-2% -$1.04K 0.04% 1038
2016
Q4 		$53K Buy
+3,833
New +$53.1K 0.02% 1367

Other funds holding LFCR

NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Acrospire Investment Management's LFCR Position: Q3 2017 in Review

Acrospire Investment Management sold out of Lifecore Biomedical (LFCR) in Q3 2017, closing a stake of 10,722 shares — an estimated $159K sold.

Acrospire Investment Management first reported a position in LFCR in Q4 2016 and held it in 3 quarters. The position peaked at $159K in Q2 2017. 95 funds tracked by Wall St. Rank hold LFCR as of Q3 2017.

  • Acrospire Investment Management reported no remaining Lifecore Biomedical position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 10,722 Lifecore Biomedical shares in Q3 2017, an estimated $159K.
  • Acrospire Investment Management first reported a position in Lifecore Biomedical in Q4 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Lifecore Biomedical position peaked at $159K in Q2 2017.
  • 95 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.